Retraction
Silencing NOB1 enhances doxorubicin antitumor activity of the papillary thyroid carcinoma in vitro and in vivo
Paper Information
Record ID:
37818
Author(s):
Journal:
Publication Date:
January 15, 2015
Retraction Date:
June 14, 2022
(3.4 years years ago)
Subjects:
Institution:
Department of Thyroid Surgery, The First Bethune Hospital of Jilin University, Changchun, Jilin 130021, P.R. ChinaCountry:
🇨🇳 ChinaArticle Type:
Publisher:
Spandidos
Open Access:
Yes
DOI:
PubMed ID:
Retraction PubMed ID:
Retraction Details
Retraction Reasons:
Nature of Retraction:
Retraction
Retraction Notice:
10.3892/or.2022.8297Additional Notes:
see also: https://pubpeer.com/publications/1E01E804BCB7B04C8B2E9A11B6DCC4
Citations (12)
12
Total Citations0
Post-Retraction12
Pre-Retraction0
Same DayAberrant expression of miRNA‐192‐5p contributes to <i>N</i>,<i>N</i>‐dimethylformamide‐induced hepatic apoptosis
Zhen Zhang, Wei Zhu, Ziqi Liu et al. (11 authors)
Journal of Applied Toxicology
Published: Jul 2020
12 citations
12 citations
704 days before retraction
NOB1: A Potential Biomarker or Target in Cancer
Weiwei Ke, Zaiming Lu, Xiangxuan Zhao
Current Drug Targets
Published: Mar 2019
12 citations
12 citations
1191 days before retraction
MicroRNA‑744 suppresses cell proliferation and invasion of papillary thyroid cancer by directly targeting NOB1
Haixia Liu, Jing Guo, Hongyan Chai et al. (4 authors)
Molecular Medicine Reports
Open Access
Published: Jan 2019
5 citations
5 citations
1257 days before retraction
Novel oxazolinoanthracyclines as tumor cell growth inhibitors—Contribution of autophagy and apoptosis in solid tumor cells death
Aneta Rogalska, Arkadiusz Gajek, Małgorzata Łukawska et al. (5 authors)
PLoS ONE
Open Access
Published: Jul 2018
15 citations
15 citations
1421 days before retraction
Effects of NOB1 on the pathogenesis of osteosarcoma and its expression on the chemosensitivity to cisplatin
Leiming Luo, Yuanhui Wang, Yiran Yin et al. (5 authors)
Oncology Letters
Open Access
Published: Jan 2018
9 citations
9 citations
1622 days before retraction
Overexpression of miR-101 promotes TRAIL-induced mitochondrial apoptosis in papillary thyroid carcinoma by targeting c-met and MCL-1
Jie Zhu, Zhenjie Li
Oncotarget
Open Access
Published: Sep 2017
11 citations
11 citations
1725 days before retraction
Paper citing Silencing NOB1 enhances doxorubicin antitumor acti...
Unknown Authors
Unknown Journal
Published: Jul 2017
1805 days before retraction
Inhibition of NOB1 by microRNA-330-5p overexpression represses cell growth of non-small cell lung cancer
Ranran Kong, Wei Liu, Yurui Guo et al. (14 authors)
Oncology Reports
Open Access
Published: Apr 2017
28 citations
28 citations
1900 days before retraction
MiR-139-3p induces cell apoptosis and inhibits metastasis of cervical cancer by targeting NOB1
Ping Huang, Jie Xi, Shikai Liu
Biomedicine & Pharmacotherapy
Published: Aug 2016
68 citations
68 citations
2137 days before retraction
NOB1 silencing inhibits the growth and metastasis of laryngeal cancer cells through the regulation of JNK signaling pathway
Xin Gao, Jin Wang, Weiliang Bai et al. (5 authors)
Oncology Reports
Open Access
Published: Mar 2016
17 citations
17 citations
2273 days before retraction
miR-192 suppresses the tumorigenicity of prostate cancer cells by targeting and inhibiting nin one binding protein
Jiantao Sun, Zhiqiang Fan, Shuaiqi Lu et al. (6 authors)
International Journal of Molecular Medicine
Open Access
Published: Jan 2016
23 citations
23 citations
2352 days before retraction
Anticancer activity of NOB1-targeted shRNA combination with TRAIL in epithelial ovarian cancer cells.
Lin Yang, Tianmin Xu, Hong Teng et al. (4 authors)
PubMed
Published: Jan 2015
5 citations
5 citations
2721 days before retraction
Quick Stats
Total Citations:
12
Years Since Retraction:
3.4 years
Open Access:
Yes
Last Checked:
Jul 24, 2025